These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 30146614)

  • 1. Cardioprotective Effects of High-Density Lipoprotein Beyond its Anti-Atherogenic Action.
    Nagao M; Nakajima H; Toh R; Hirata KI; Ishida T
    J Atheroscler Thromb; 2018 Oct; 25(10):985-993. PubMed ID: 30146614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atheroprotective effects of HDL: beyond reverse cholesterol transport.
    Feig JE; Shamir R; Fisher EA
    Curr Drug Targets; 2008 Mar; 9(3):196-203. PubMed ID: 18336237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease.
    Chapman MJ
    Pharmacol Ther; 2006 Sep; 111(3):893-908. PubMed ID: 16574234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cholesteryl ester transfer protein (CETP) inhibition beyond raising high-density lipoprotein cholesterol levels: pathways by which modulation of CETP activity may alter atherogenesis.
    Klerkx AH; El Harchaoui K; van der Steeg WA; Boekholdt SM; Stroes ES; Kastelein JJ; Kuivenhoven JA
    Arterioscler Thromb Vasc Biol; 2006 Apr; 26(4):706-15. PubMed ID: 16439711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low high-density lipoprotein cholesterol: physiological background, clinical importance and drug treatment.
    Hersberger M; von Eckardstein A
    Drugs; 2003; 63(18):1907-45. PubMed ID: 12930163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beyond LDL-cholesterol: HDL-cholesterol as a target for atherosclerosis prevention.
    Parhofer KG
    Exp Clin Endocrinol Diabetes; 2005 Sep; 113(8):414-7. PubMed ID: 16151973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cholesterol reduction and atherosclerosis inhibition by bezafibrate in low-density lipoprotein receptor knockout mice.
    Inaba T; Yagyu H; Itabashi N; Tazoe F; Fujita N; Nagashima S; Okada K; Okazaki M; Furukawa Y; Ishibashi S
    Hypertens Res; 2008 May; 31(5):999-1005. PubMed ID: 18712055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HDL-C: role as a risk modifier.
    Barter P
    Atheroscler Suppl; 2011 Nov; 12(3):267-70. PubMed ID: 22152280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-density lipoprotein and atherosclerosis: the role of antioxidant activity.
    Bandeali S; Farmer J
    Curr Atheroscler Rep; 2012 Apr; 14(2):101-7. PubMed ID: 22441969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Have we forgotten the pivotal role of high-density lipoprotein cholesterol in atherosclerosis prevention?
    Wierzbicki AS
    Curr Med Res Opin; 2005 Feb; 21(2):299-306. PubMed ID: 15802001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolving concepts of the role of high-density lipoprotein in protection from atherosclerosis.
    Farmer JA; Liao J
    Curr Atheroscler Rep; 2011 Apr; 13(2):107-14. PubMed ID: 21380938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current concept of reverse cholesterol transport and novel strategy for atheroprotection.
    Ono K
    J Cardiol; 2012 Nov; 60(5):339-43. PubMed ID: 23063661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ecto-F1-ATPase/P2Y pathways in metabolic and vascular functions of high density lipoproteins.
    Martinez LO; Najib S; Perret B; Cabou C; Lichtenstein L
    Atherosclerosis; 2015 Jan; 238(1):89-100. PubMed ID: 25437896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-density lipoproteins, inflammation and oxidative stress.
    Tabet F; Rye KA
    Clin Sci (Lond); 2009 Jan; 116(2):87-98. PubMed ID: 19076062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Attenuation of atherogenic apo B-48-dependent hyperlipidemia and high density lipoprotein remodeling induced by vitamin C and E combination and their beneficial effect on lethal ischemic heart disease in mice.
    Contreras-Duarte S; Chen P; Andía M; Uribe S; Irarrázaval P; Kopp S; Kern S; Marsche G; Busso D; Wadsack C; Rigotti A
    Biol Res; 2018 Sep; 51(1):34. PubMed ID: 30219096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ; Yellon DM
    Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low high-density lipoprotein cholesterol: an important consideration in coronary heart disease risk assessment.
    Majeed F; Miller M
    Curr Opin Endocrinol Diabetes Obes; 2008 Apr; 15(2):175-81. PubMed ID: 18316954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ; Yellon DM
    Postgrad Med J; 2008 Nov; 84(997):590-8. PubMed ID: 19103817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cholesterol efflux and reverse cholesterol transport.
    Favari E; Chroni A; Tietge UJ; Zanotti I; Escolà-Gil JC; Bernini F
    Handb Exp Pharmacol; 2015; 224():181-206. PubMed ID: 25522988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.